Correction: Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting

Key Points

• To correct previous findings regarding the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors.
• Revising previous study data and analyses related to gastramide theranostics.
• Focusing on preclinical outcomes regarding the effectiveness of the treatment.
• Ensuring the reliability of therapeutic efficacy conclusions.
• Clarified findings on the efficacy of gastramide in targeting cholecystokinin-2 receptors.
• Highlighted the necessity of corrections for accurate scientific reporting.